Martine Piccart, Md, PhD
Jules Bordet Institute · Institut Jules Bordet, Brussels, Belgium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martine Piccart, Md, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07753954 · Medical Imaging to Re-evaluate Elacestrant Clinical UsageJules Bordet Institute · not yet recruiting · ER+ / HER2- Advanced Breast Cancer · study chair
- Ph2NCT06595563 · HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerJules Bordet Institute · terminated · HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer · study chair
- Ph1NCT03767335 · MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast CancerMenarini Group · completed · Advanced or Metastatic Breast Cancer
- N/ANCT02094742 · BIG Molecular Screening Feasibility StudyJules Bordet Institute · completed · Metastatic Breast Cancer · principal investigator
- Ph2NCT00162812 · Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of EpirubicinJules Bordet Institute · terminated · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.